Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Korea Stock Exchange  >  Celltrion, Inc.    A068270   KR7068270008

CELLTRION, INC.

(A068270)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Celltrion : South Korea's Celltrion gets approval for Phase 3 trials of COVID-19 antibody drug

10/12/2020 | 12:56am EST
Flags bearing the South Korean national flag and Celltrion's flag flutter in the wind at the company's headquarters in Incheon

SEOUL (Reuters) - South Korean drugmaker Celltrion Inc said on Monday it has received regulatory approval for Phase 3 clinical trials of an experimental COVID-19 treatment.

The approval comes as the company plans to seek conditional approval for its antibody drug, CT-P59, for emergency use by the end of this year.

The treatment, the most advanced antibody drug in terms of research in South Korea, is directed against the surface of the virus and designed to block it from locking on to human cells.

The third stage trials will be conducted on some 1,000 asymptomatic coronavirus patients and those who have come into close contact with COVID-19 patients in Korea, Celltrion said in a statement.

The Ministry of Food and Drug Safety recently approved a Phase 2/3 study on patients with mild and moderate cases of COVID-19, Lee Sang-joon, Celltrion's senior executive vice president, told Reuters.

Celltrion began commercial production of the drug in September - likely to amount to around 1 million doses - in anticipation of demand in both domestic and overseas markets.

In July, Celltrion separately launched overseas human trials of its treatment in Britain.

(Reporting by Sangmi Cha; Editing by Kenneth Maxwell)

By Sangmi Cha


© Reuters 2020
All news about CELLTRION, INC.
11/26CELLTRION : Phase II trial to study anti-COVID-19 mAb CT-P59 completes enrolment
AQ
11/06CELLTRION, INC. : quaterly earnings release
11/05Celltrion's COVID-19 antibody drug cut recovery time-early study
RE
11/05CELLTRION HEALTHCARE : says Phase 1 trial shows COVID-19 antibody drug 'well-tol..
RE
11/04S.Korea shares extend gains as investors eye tight U.S. election race
RE
11/03S.Korea stocks gain most in nearly 5 months on strong global data
RE
10/27S.Korea begins preliminary review of AstraZeneca's COVID-19 vaccine candidate
RE
10/26S.Korea shares dip as surging global coronavirus cases dent sentiment
RE
10/26South Korea pharma Celltrion's COVID test gets U.S. emergency use authorisati..
RE
10/25S.Korea pharma Celltrion's COVID test gets U.S. emergency use authorisation
RE
More news
Financials
Sales 2020 1 874 B 1,69 B 1,69 B
Net income 2020 583 B 0,53 B 0,53 B
Net cash 2020 500 B 0,45 B 0,45 B
P/E ratio 2020 78,2x
Yield 2020 0,00%
Capitalization 45 485 B 41 055 M 41 073 M
EV / Sales 2020 24 269x
EV / Sales 2021 21 009x
Nbr of Employees 908
Free-Float 68,3%
Chart CELLTRION, INC.
Duration : Period :
Celltrion, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELLTRION, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 317 578,95 KRW
Last Close Price 340 000,00 KRW
Spread / Highest target 32,4%
Spread / Average Target -6,59%
Spread / Lowest Target -64,1%
EPS Revisions
Managers
NameTitle
Wu-Sung Ki Chief Executive Officer & Director
Jung-Jin Seo Chairman
Ho-Seop Lee Finance Director
Dong-Il Kim Independent Director
Joseph Lee Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.82.04%40 460
MODERNA, INC.549.44%50 267
LONZA GROUP AG56.23%45 319
IQVIA HOLDINGS INC.9.26%32 365
SEAGEN INC.48.01%30 493
IMMUNOMEDICS, INC.315.22%20 324